Altair Therapeutics Secures $17M Financing

Altair Therapeutics, Inc., a San Diego, CA-based biopharmaceutical company developing novel therapeutics for respiratory diseases, has secured a $17m equity financing.
The round was led by Domain Associates, LLC with particpation from AgeChem Venture Fund LP, which joined previous investors Thomas, McNerney & Partners, LLC, Forward Ventures and Isis Pharmaceuticals, Inc.
The proceeds will be used to complete phase 2a trials for the company’s flagship product, inhaled AIR645, and advance research and development in new target programs.

Join the discussion